FDA grants breakthrough nod to patient monitor for organ failure from Opticyte

The Cell O2 patient monitor. [Image from Opticyte website]Opticyte announced today that its Cell O2 patient monitor received breakthrough device designation from the FDA.

Seattle-based Opticyte designed Cell O2 to use noninvasive optical spectroscopy technology. It measures and detects systemic low oxygen levels inside cells. This provides continuous monitoring of cellular oxygen levels during hospitalization.

The startup said in a news release it could reduce organ failure for those with sepsis, trauma and myocardial infarction.

“We’re pleased the FDA recognized the strength of our data and the promise of our technology to deliver reliable and actionable cellular oxygenation readings for medical staff–often working in emergency medicine–to more effectively prevent organ failure and save lives,” said Lori Arakaki, Opticyte co-founder and CEO. “This new designation will allow us to more quickly reach sepsis, trauma, and cardiac surgery patients with organ dy…

Read more
  • 0